Daré Bioscience Financial Ratios Analysis
Valuation, profitability, leverage, and liquidity ratios
| Breakdown | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
| Valuation Ratios | ||||||
| P/S Ratio | 26.77 | 2774.45 | 10.85 | 7.04 | - | - |
| P/B Ratio | 9.70 | -4.51 | -6.03 | 6.34 | 3.95 | -47.78 |
| Price/Tangible Book | 9.70 | - | - | 6.34 | 3.95 | - |
| Price/FCF | - | 5.54 | - | - | - | - |
| Price/OCF | - | 4.96 | - | - | - | - |
| Enterprise Value Ratios | ||||||
| EV/Revenue | 12.29 | 1769.85 | 5.97 | 3.06 | - | - |
| EV/FCF | - | 3.53 | - | - | - | - |
| Profitability & Returns | ||||||
| Return on Equity (ROE) | - | - | −994.69% | −124.12% | −205.82% | - |
| Return on Assets (ROA) | −49.10% | −18.69% | −92.65% | −62.12% | −122.15% | −228.45% |
| Return on Capital Employed (ROCE) | −154.20% | −4805.00% | −3834.00% | −257.20% | −98.30% | 24936.30% |
| Leverage & Solvency Ratios | ||||||
| Debt/Equity | 2.83 | -1.01 | -0.28 | 0.04 | 0.01 | -0.66 |
| Debt/FCF | - | 1.24 | - | - | - | - |
| Liquidity Ratios | ||||||
| Current Ratio | 1.14 | 0.85 | 0.86 | 1.36 | 3.44 | 0.91 |
| Quick Ratio | 1.07 | 0.74 | 0.56 | 1.15 | 3.29 | 0.67 |
| Efficiency Ratios | ||||||
| Asset Turnover | 0.04 | 0.00 | 0.09 | 0.20 | - | - |
| Yield & Distribution Ratios | ||||||
| Earnings Yield | −48.59% | −14.93% | −99.03% | −43.96% | −25.26% | −49.80% |
| FCF Yield | −37.24% | 18.05% | −129.65% | −25.78% | −18.78% | −45.89% |
| Buyback Yield | −31.55% | −16.80% | −3.23% | −38.29% | −103.23% | −93.15% |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
